# Cell energy and getting through the afternoon

Cellular energy

How a cell handles fuel is one question. How tired you feel is another.

MOTS-c and NAD+ both lead into research on how cells handle fuel. I’ve put them together to make that connection easier to read. It doesn’t mean they’ve been tested as a pair, or that either will make a tiring day easier.

## Energy in a cell and energy on a staircase

“Energy” can mean a chemical reaction or enough get-up-and-go to carry laundry upstairs. Same word, rather different questions. I look for which one a paper actually tested.

[NAD+ helps cells turn fuel into usable energy](https://pubmed.ncbi.nlm.nih.gov/34041853/). Its full name is nicotinamide adenine dinucleotide. It’s a coenzyme, a small helper molecule, rather than a peptide. You don’t need to memorise the name to see why it belongs in this conversation.

The useful question is what changed for the person. A result inside a cell leaves that part of the story open.

![Side view of an adult’s thigh and calf muscles during a single step up a broad white stair.](/nexus-between-e0d651e57312/effort-on-the-stairs.webp)

A stair step puts the thigh muscles to work. MOTS-c mouse findings and NAD+ biology do not tell us whether a person will find that step easier.

## MOTS-c connects cell stress with fuel handling

MOTS-c is a short peptide whose recipe sits in mitochondria, the cell’s energy-making structures. In the [first cell and mouse study](https://pubmed.ncbi.nlm.nih.gov/25738459/), treated mice on a high-fat diet gained less weight and handled sugar better than untreated mice.

What about people? FDA’s [review found no published studies giving MOTS-c to humans](https://www.fda.gov/media/193347/download). A [registered trial in adults with prediabetes, a blood-sugar condition, and extra weight](https://clinicaltrials.gov/study/NCT07505745) sets out a test, but supplies no results.

A trial plan is worth knowing about. It’s also worth leaving the answer blank until there is one.

## NAD+ has a precursor problem in the wording

NMN, nicotinamide mononucleotide, and NR, nicotinamide riboside, are precursors: materials the body uses to make NAD+. Giving one of those isn’t the same as giving NAD+ itself.

One [NMN trial in women past menopause who had prediabetes](https://pubmed.ncbi.nlm.nih.gov/33888596/) found that muscle responded better to insulin, the hormone that helps manage blood sugar. Neither body composition nor a measure of blood sugar over time changed in that trial. That doesn’t answer whether someone feels less tired.

A [review of human precursor trials](https://pubmed.ncbi.nlm.nih.gov/37068054/) found changes in NAD-related measurements more consistently than gains in how people functioned. A better-looking measurement can still leave the stairs feeling like stairs.

## The safety question stays open

MOTS-c is not FDA-approved. Its [human safety is unknown, and basic animal safety tests are missing](https://www.fda.gov/media/193347/download). For injected forms, FDA flags impurities, clumping and unwanted immune reactions. These are concerns, not measured rates of harm in people.

The [precursor studies had limited follow-up](https://pubmed.ncbi.nlm.nih.gov/37068054/). They don’t establish long-term safety or the safety of NAD+ infusions. Persistent tiredness is a question for a licensed U.S. clinician who can assess the symptom itself.